ExploreWatchlistsPricing
  1. US-listed companies
  2. Theravance Biopharma, Inc.
  3. Financials
  4. Net income margin (%)

Theravance Biopharma, Inc. (TBPH)

Market cap
$849.63M
P/E ratio
8x
SummaryFinancials
Period EndNet income margin (%) YoY (%)
Dec 31, 202598.5-212.45%
Dec 31, 2024-87.6-8.83%
Dec 31, 2023-96.1-105.66%
Dec 31, 20221,698.5-571.09%
Dec 31, 2021-360.6-6.81%
Dec 31, 2020-386.9+20.12%
Dec 31, 2019-322.1-9.78%
Dec 31, 2018-357-80.75%
Dec 31, 2017-1,855+373.28%
Dec 31, 2016-391.9-9.39%
Dec 31, 2015-432.6-78.67%
Dec 31, 2014-2,028

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat